Trials / Completed
CompletedNCT01242527
Epanova® for Lowering Very High Triglycerides
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 399 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo | 4 capsules (1g) daily for 12 weeks |
| DRUG | omefas | 2 capsules (1g) + 2 placebo daily for 12 weeks |
| DRUG | omefas | 3 capsules (1g) + 1 placebo daily for 12 weeks |
| DRUG | omefas | 4 capsules (1g)daily for 12 weeks |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2012-03-01
- Completion
- 2012-04-01
- First posted
- 2010-11-17
- Last updated
- 2016-08-04
- Results posted
- 2013-09-06
Locations
68 sites across 7 countries: United States, Denmark, Hungary, India, Netherlands, Russia, Ukraine
Source: ClinicalTrials.gov record NCT01242527. Inclusion in this directory is not an endorsement.